Navigation Links
Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance
Date:4/28/2008

eferred compensation plan liabilities 454 269

Net cash provided by operating activities 67,520 32,928

Investing activities:

Proceeds from sales and maturities of short-term

investments 97,290 14,819

Purchases of short-term investments (181,546) (65,863)

Purchases of property, plant and equipment (20,033) (5,894)

Capitalization of intangible assets, including

license and manufacturing access fees (194) (1,817)

Sale of stock holdings of Molecular Profiling

Institute, Inc. 4,100 -

Other items, net 75 (352)

Net cash used in investing activities (100,308) (59,107)

Financing activities:

Repurchase and retirement of restricted stock for

payment of taxes (41) -

Excess tax benefit from employee stock options 145 1,284

Proceeds from issuance of common stock 3,027 4,402

Net cash provided by financing activities 3,131 5,686

Effect of exchange rate changes on cash and cash

equivalents (7) 16

Net decrease in cash and cash equivalents (29,664) (20,477)

Cash and cash equivalents at the beginning of

period 75,963 87,905

Cash and cash equivalents at the end of period $46,299 $67,428


'/>"/>
SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Gen-Probe to Webcast Presentation at Morgan Stanley Global Healthcare Unplugged Conference
2. Gen-Probe to Webcast Presentations at Lehman and Cowen Healthcare Conferences
3. Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007
4. Carl Hull Named President and Chief Operating Officer of Gen-Probe
5. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
6. Gen-Probe to Webcast Three Upcoming Presentations
7. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
8. Gen-Probe to Webcast Presentation at Bank of Americas 37th Annual Investment Conference
9. Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder
10. CV Therapeutics Reports 2008 First Quarter Financial Results
11. Caliper Life Sciences Reports West Coast Consolidation of Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... Colo. and BANGALORE, India ... global genomic profiling company that uses next generation sequencing ... of Scott A. Storrer as chief executive ... CEO, he will be responsible for all strategy, business ... Chandru , who has served as Strand,s chairman and ...
(Date:7/1/2015)... , July 1, 2015 InferMed ... technology will ... evidence-based clinical s olutions suite   ... and medical information products and services, announced today the acquisition ... decision support (CDS) technology company. InferMed,s Arezzo technology ...
(Date:6/30/2015)... ... June 30, 2015 , ... Students and faculty ... the first half of “Integrative Biotechnology,” an applied biotechnology course team-taught by faculty ... this course combines students from both universities and is taught on both continents. ...
(Date:6/30/2015)... -- Today, Americord Registry, one of the fastest growing cord blood ... partner at Kirkland & Ellis LLP, as the newest member ... http://photos.prnewswire.com/prnh/20150630/226958LOGO   "We are thrilled about Andrew ... Smithmyer , CEO of Americord. "He brings a wealth of ... Americord,s growth and vision." Andrew Horne ...
Breaking Biology Technology:Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2Americord Registry Announces Andrew Horne as Advisory Board Member 2
... patients with cutaneous T-cell lymphoma on schedule for completion ... June 29 Yaupon Therapeutics, a privately held specialty ... a pivotal Phase 2 clinical trial for Clearazide for ... stages 1-2a). The study, which is being conducted ...
... , PRINCETON, N.J., June 29 DOR ... (OTC Bulletin Board: DORB), a late-stage biopharmaceutical company, announced ... Center, Seattle, Washington, published a paper this morning in ... that DOR,s lead product orBec(R) (oral beclomethasone dipropionate or ...
... - YM BioSciences Inc. (NYSE Amex: YMI ... company that identifies and advances a diverse portfolio ... development, today reported that YM,s subsidiary, CIMYM BioSciences ... between the companies in a cooperative effort. CIMYM ...
Cached Biology Technology:Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cutaneous T-cell Lymphoma 2DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation 2DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation 3DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation 4DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation 5DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation 6YM BIOSCIENCES' SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG 2YM BIOSCIENCES' SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG 3YM BIOSCIENCES' SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG 4
(Date:6/24/2015)... 2015 The biologics safety testing market is ... the market include growth of the pharmaceutical and biological ... Over the years, the number of drug approvals in ... the FDA approved 225 drug applications and Health Canada ... Europe accounted for 3,822 of the pharmaceutical ...
(Date:6/24/2015)... 22, 2015 Research ... of the "Huawei Ascend Mate 7 Fingerprint ... their offering. Huawei,s technological choice for ... direction than Apple,s and Samsung,s one. The Ascend ... by Fingerprint Cards, a main actor in capacitive ...
(Date:6/23/2015)... DUBLIN , June 22, 2015 ... has announced the addition of the "Body-Worn ... Share, Growth, Trends and Forecast 2014 - 2020" ... report offers strategic analysis of the global body-worn ... market has been segmented on the basis of ...
Breaking Biology News(10 mins):Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2
... was recently discovered in the cloud-forests of Peru. The large ... a bit like one, except its closest relatives are spiny ... yet strange looking, with long dense fur, a broad blocky ... on the crown, nape and shoulders add to its distinctive ...
... Washington University School of Medicine in St. Louis, living ... Then, because of the unusual meal, the cells were ... mice. , Developed in the laboratories of Samuel ... nanoparticles could soon allow researchers and physicians to directly ...
... to develop a quick, simple and cheap immune-system test for ... in the poorest countries get appropriate treatment to extend their ... , The work is part of an $8.6 million international ... London and funded by the Bill and Melinda Gates Foundation. ...
Cached Biology News:Scientists discover new species of distinctive cloud-forest rodent 2Nanoparticles can track cells deep within living organisms 2Nanoparticles can track cells deep within living organisms 3Cornell researcher helping develop quick, cheap HIV/AIDS test 2
SAPK/JNK Antibody...
Mouse monoclonal [DJR3] to DcR1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
Tris-EDTA Buffer Solution, 1X, pH 8.0, sterile, Molecular Biology Grade...
Component in MasterPure™ Purification Kits...
Biology Products: